Literature DB >> 3166889

A tumour spheroid model for antibody-targeted therapy of micrometastases.

K A Walker1, T Murray, T E Hilditch, T E Wheldon, A Gregor, I M Hann.   

Abstract

Human neuroblastoma cells grown as tumour spheroids were briefly incubated with a conjugate of 131I and an anti-human neuroectodermal monoclonal antibody UJ13A. Unbound 131I was removed by washing and the spheroids observed in culture conditions for up to 4 weeks. Spheroid response to irradiation was evaluated as time to reach 10x treatment volume and proportion of spheroids sterilised. Spheroid growth was found to be affected by both the activity of 131I-UJ13A and the duration of the incubation. Na[131I], 131I-HSA, 131I labelled non-specific antibody and unlabelled antibody were found to be relatively ineffective compared to 131I-UJ13A. The tumour spheroid model has applications in the evaluation of antibodies or antibody fragments and different radionuclides which may be considered for radioimmunotherapy of micrometastases.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3166889      PMCID： PMC2246487          DOI： 10.1038/bjc.1988.152

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  13 in total

1.  A simplified method for production and growth of multicellular tumor spheroids.

Authors:  J M Yuhas; A P Li; A O Martinez; A J Ladman
Journal:  Cancer Res       Date:  1977-10       Impact factor: 12.701

2.  Growth of multicell spheroids in tissue culture as a model of nodular carcinomas.

Authors:  R M Sutherland; J A McCredie; W R Inch
Journal:  J Natl Cancer Inst       Date:  1971-01       Impact factor: 13.506

3.  Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies.

Authors:  S E Order; J L Klein; D Ettinger; P Alderson; S Siegelman; P Leichner
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-06       Impact factor: 7.038

4.  Distribution of IgM monoclonal antibody in mice with human tumour xenografts: lack of tumour localization.

Authors:  M V Pimm; R W Baldwin
Journal:  Eur J Cancer Clin Oncol       Date:  1985-06

5.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

6.  The radiosensitivity of human neuroblastoma cells estimated from regrowth curves of multicellular tumour spheroids.

Authors:  T E Wheldon; A Livingstone; L Wilson; J O'Donoghue; A Gregor
Journal:  Br J Radiol       Date:  1985-07       Impact factor: 3.039

7.  Biological characterization and clinical applications of a monoclonal antibody recognizing an antigen restricted to neuroectodermal tissues.

Authors:  P M Allan; J A Garson; E I Harper; U Asser; H B Coakham; B Brownell; J T Kemshead
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

8.  Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments.

Authors:  J A Carrasquillo; K A Krohn; P Beaumier; R W McGuffin; J P Brown; K E Hellström; I Hellström; S M Larson
Journal:  Cancer Treat Rep       Date:  1984-01

9.  Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy.

Authors:  G W West; R Weichselbaum; J B Little
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

10.  Tumor size: effect on monoclonal antibody uptake in tumor models.

Authors:  P L Hagan; S E Halpern; R O Dillman; D L Shawler; D E Johnson; A Chen; L Krishnan; J Frincke; R M Bartholomew; G S David
Journal:  J Nucl Med       Date:  1986-03       Impact factor: 10.057
View more
  9 in total

1.  Effects of 131I-EGF on cultured human glioma cells.

Authors:  J Capala; M Pråhl; S Scott-Robson; J Pontén; B Westermark; J Carlsson
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

2.  Effects of EGF-dextran-tyrosine-131I conjugates on the clonogenic survival of cultured glioma cells.

Authors:  A Andersson; J Capala; J Carlsson
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

3.  Homogeneous penetration but heterogeneous binding of antibodies to carcinoembryonic antigen in human colon carcinoma HT-29 spheroids.

Authors:  J Carlsson; E Daniel-Szolgay; G Frykholm; B Glimelius; A Hedin; B Larsson
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-G.

Authors:  R J Mairs; M N Gaze; A Barrett
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

5.  The distribution of alternative agents for targeted radiotherapy within human neuroblastoma spheroids.

Authors:  R J Mairs; W Angerson; M N Gaze; T Murray; J W Babich; R Reid; C McSharry
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

6.  Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.

Authors:  M L Hauck; R H Larsen; P C Welsh; M R Zalutsky
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.

Authors:  M N Gaze; R J Mairs; S M Boyack; T E Wheldon; A Barrett
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

8.  Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin.

Authors:  R Chignola; R Foroni; A Franceschi; M Pasti; C Candiani; C Anselmi; G Fracasso; G Tridente; M Colombatti
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

9.  Morphogenetic and neuronal characterization of human neuroblastoma multicellular spheroids cultured under undifferentiated and all-trans-retinoic acid-differentiated conditions.

Authors:  Gwon-Soo Jung; Kyeong-Min Lee; Jin-Kyu Park; Seong-Kyoon Choi; Won Bae Jeon
Journal:  BMB Rep       Date:  2013-05       Impact factor: 4.778
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.